Monferrer E, et al. - Authors assessed 563 primary neuroblastic tumors (NBTs) to explain the clinical consequence of Oct4 (a transcription factor crucial to mammal embryonic development and stem cell fate regulation) in NBTs. They observed no Oct4 expression in ganglioneuroma. They also found a link between high Oct4 expression levels, high-risk cases as per the International Neuroblastoma Risk Group pre-treatment classification parameters, larger blood vessels, and low survival rates. They noted that tumors with a high percentage of cells expressing Oct4 were related with undifferentiated and poorly differentiated neuroblastoma / nodular ganglioneuroblastoma. Therefore, the Oct4 gene could be a target for knockdown when creating different treatments for high-risk NBT patients.